Abecma(idecabtagene vicleucel)
Abecma (idecabtagene vicleucel) is a gene pharmaceutical. Idecabtagene vicleucel was first approved as Abecma on 2021-03-03. It is used to treat multiple myeloma in the USA. It has been approved in Europe to treat blood protein disorders, cardiovascular diseases, hematologic diseases, hemic and lymphatic diseases, and hemorrhagic disorders amongst others.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Abecma
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| abecma | Biologic Licensing Application | 2025-11-25 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| multiple myeloma | — | D009101 | C90.0 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
idecabtagene vicleucel, Abecma, Celgene Corporation, a Bristol-Myers Squibb Company | |||
| 2028-03-26 | Orphan excl. | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code | Description |
|---|---|
| Q2055 | Idecabtagene vicleucel, up to 460 million autologous b-cell maturation antigen (bcma) directed car-positive t cells, including leukapheresis and dose preparation procedures, per therapeutic dose |
Clinical
Clinical Trials
121 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple myeloma | D009101 | — | C90.0 | 55 | 35 | 2 | 1 | 11 | 89 |
| Recurrence | D012008 | — | — | 2 | 1 | — | 1 | — | 3 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | 1 | — | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Plasma cell neoplasms | D054219 | — | — | 47 | 25 | 2 | — | 8 | 70 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | 8 | 1 | — | — | — | 8 |
| Leukemia | D007938 | — | C95 | 2 | 4 | — | — | 1 | 6 |
| Plasma cell leukemia | D007952 | — | C90.1 | 1 | 3 | — | — | 1 | 5 |
| Lymphoma | D008223 | — | C85.9 | 2 | 1 | — | — | 1 | 3 |
| Amyloidosis | D000686 | EFO_1001875 | E85 | 1 | 2 | — | — | 1 | 3 |
| Immunoglobulin g4-related disease | D000077733 | — | D89.84 | 2 | 1 | — | — | — | 3 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | — | 1 | — | — | 1 | 2 |
| B-cell lymphoma | D016393 | — | — | — | 1 | — | — | 1 | 2 |
| Healthy volunteers/patients | — | — | — | 2 | 1 | — | — | — | 2 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | 1 | 1 | — | — | — | 2 |
Show 3 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | 5 | — | — | — | 2 | 7 |
| Anti-neutrophil cytoplasmic antibody-associated vasculitis | D056648 | — | I77.82 | 6 | — | — | — | — | 6 |
| Systemic scleroderma | D012595 | EFO_0000717 | M34 | 6 | — | — | — | — | 6 |
| Myasthenia gravis | D009157 | EFO_0004991 | G70.0 | 4 | — | — | — | — | 4 |
| Hemolytic anemia autoimmune | D000744 | EFO_1001264 | D59.10 | 3 | — | — | — | — | 3 |
| Hemolytic anemia | D000743 | — | D55-D59 | 3 | — | — | — | — | 3 |
| Myositis | D009220 | EFO_0000783 | G72.49 | 3 | — | — | — | — | 3 |
| Syndrome | D013577 | — | — | 2 | — | — | — | — | 2 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | — | — | — | 1 | 2 |
| Vasculitis | D014657 | EFO_0006803 | M31 | 2 | — | — | — | — | 2 |
Show 35 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vaccine-preventable diseases | D000079263 | — | — | — | — | — | — | 1 | 1 |
| B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | — | — | — | — | 1 | 1 |
| B-cell leukemia | D015448 | — | — | — | — | — | — | 1 | 1 |
| Immunoglobulin light-chain amyloidosis | D000075363 | — | — | — | — | — | — | 1 | 1 |
| Lymphoid leukemia | D007945 | — | C91 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Idecabtagene vicleucel |
| INN | idecabtagene vicleucel |
| Description | Idecabtagene vicleucel, sold under the brand name Abecma, is a cell-based gene therapy to treat multiple myeloma.
|
| Classification | Gene |
| Drug class | Antineoplastic |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL4298199 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 8PX1X7UG4D (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Abecma – Bristol Myers Squibb
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,665 documents
View more details
Safety
Black-box Warning
Black-box warning for: Abecma
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,129 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use